Literature DB >> 27518686

Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.

Amy W Zhou1, Eric M Knoche1, Elizabeth K Engle1, Makiko Ban-Hoefen2, Charu Kaiwar3, Stephen T Oh3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27518686      PMCID： PMC5007138          DOI： 10.1056/NEJMc1600337

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Complications in children and adolescents with Chuvash polycythemia.

Authors:  Adelina I Sergueeva; Galina Y Miasnikova; Lydia A Polyakova; Mehdi Nouraie; Josef T Prchal; Victor R Gordeuk
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

2.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Authors:  Sonny O Ang; Hua Chen; Kiichi Hirota; Victor R Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I Sergueeva; Galina Y Miasnikova; David Mole; Patrick H Maxwell; David W Stockton; Gregg L Semenza; Josef T Prchal
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

3.  [Familial erythrocytosis among the residents of the Chuvash ASSR].

Authors:  L A Poliakova
Journal:  Probl Gematol Pereliv Krovi       Date:  1974-10

Review 4.  Vascular complications in Chuvash polycythemia.

Authors:  Victor R Gordeuk; Josef T Prchal
Journal:  Semin Thromb Hemost       Date:  2006-04       Impact factor: 4.180

5.  Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.

Authors:  Ryan C Russell; Roxana I Sufan; Bing Zhou; Pardeep Heir; Severa Bunda; Stephanie S Sybingco; Samantha N Greer; Olga Roche; Samuel A Heathcote; Vinca W K Chow; Lukasz M Boba; Terri D Richmond; Michele M Hickey; Dwayne L Barber; David A Cheresh; M Celeste Simon; Meredith S Irwin; William Y Kim; Michael Ohh
Journal:  Nat Med       Date:  2011-06-19       Impact factor: 53.440
  5 in total
  5 in total

Review 1.  Genetic Background of Congenital Erythrocytosis.

Authors:  Mary Frances McMullin
Journal:  Genes (Basel)       Date:  2021-07-28       Impact factor: 4.096

2.  Translational repression of HIF2α expression in mice with Chuvash polycythemia reverses polycythemia.

Authors:  Manik C Ghosh; De-Liang Zhang; Hayden Ollivierre; Michael A Eckhaus; Tracey A Rouault
Journal:  J Clin Invest       Date:  2018-02-26       Impact factor: 14.808

3.  Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases.

Authors:  Manik C Ghosh; De-Liang Zhang; Wade H Ollivierre; Audrey Noguchi; Danielle A Springer; W Marston Linehan; Tracey A Rouault
Journal:  Blood       Date:  2021-05-06       Impact factor: 25.476

Review 4.  A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

Authors:  Mary F F McMullin; Adam J Mead; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Claire N Harrison
Journal:  Br J Haematol       Date:  2018-11-13       Impact factor: 6.998

Review 5.  JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.

Authors:  Naseema Gangat; Natasha Szuber; Animesh Pardanani; Ayalew Tefferi
Journal:  Leukemia       Date:  2021-05-21       Impact factor: 11.528
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.